Banque Cantonale Vaudoise Sells 507 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Banque Cantonale Vaudoise lowered its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 24.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,550 shares of the medical equipment provider’s stock after selling 507 shares during the period. Banque Cantonale Vaudoise’s holdings in Lantheus were worth $96,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Tucker Asset Management LLC increased its position in shares of Lantheus by 239.0% in the third quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 282 shares during the period. Principal Securities Inc. bought a new position in shares of Lantheus in the fourth quarter worth $28,000. Covestor Ltd increased its position in shares of Lantheus by 62.7% in the third quarter. Covestor Ltd now owns 527 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 203 shares during the period. Parkside Financial Bank & Trust increased its position in shares of Lantheus by 36.6% in the third quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 156 shares during the period. Finally, NBC Securities Inc. increased its position in shares of Lantheus by 28.4% in the first quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider’s stock worth $53,000 after purchasing an additional 191 shares during the period. Institutional investors own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Mizuho raised their price objective on Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, May 3rd. B. Riley raised their price objective on Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a research note on Thursday, April 18th. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, May 3rd. Finally, Truist Financial raised their price objective on Lantheus from $82.00 to $96.00 and gave the company a “buy” rating in a research note on Friday, May 3rd. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Lantheus presently has an average rating of “Moderate Buy” and a consensus price target of $99.17.

Lantheus Stock Performance

Shares of LNTH stock opened at $78.95 on Tuesday. The business’s 50-day moving average price is $75.95 and its 200-day moving average price is $65.76. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $92.87. The firm has a market capitalization of $5.47 billion, a price-to-earnings ratio of 12.05 and a beta of 0.56. The company has a current ratio of 4.84, a quick ratio of 4.55 and a debt-to-equity ratio of 0.59.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.51 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.11. The firm had revenue of $369.98 million for the quarter, compared to analyst estimates of $349.46 million. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. Equities research analysts forecast that Lantheus Holdings, Inc. will post 6.51 EPS for the current year.

Insider Buying and Selling

In related news, insider Daniel Niedzwiecki sold 12,873 shares of Lantheus stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $79.86, for a total value of $1,028,037.78. Following the transaction, the insider now directly owns 80,244 shares of the company’s stock, valued at $6,408,285.84. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Lantheus news, CAO Andrea Sabens sold 341 shares of Lantheus stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $79.77, for a total value of $27,201.57. Following the completion of the sale, the chief accounting officer now directly owns 62,557 shares in the company, valued at $4,990,171.89. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Daniel Niedzwiecki sold 12,873 shares of Lantheus stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $79.86, for a total value of $1,028,037.78. Following the completion of the sale, the insider now owns 80,244 shares of the company’s stock, valued at $6,408,285.84. The disclosure for this sale can be found here. Insiders have sold a total of 32,269 shares of company stock valued at $2,557,300 over the last ninety days. 1.50% of the stock is owned by company insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.